Transplantation for children with acute lymphoblastic leukemia

Bone Marrow Transplantation
Ra Krance

Abstract

EFS for children with ALL continues to increase and is predicted to reach 90% with current therapy. Better understanding of leukemia cell biology and pharmacogenetics has led to the design of more effective treatment and also refined the prognostic features associated with a poor outcome. ALL characterized by the translocation t(9;22) or t(4;11), or by a hypodiploid karyotype or by an incomplete response to induction therapy is likely to relapse. SCT for ALL is largely used to treat patients failing primary chemotherapy but is selectively included as part of initial therapy for children at high risk for relapse. If SCT is going to become the primary therapy for children with ALL in first remission, the regimen-related mortality must approach 0%, and the risk for severe acute and chronic GVHD should be less than 5%. Salvage therapy after ALL relapse remains the major indication for SCT. The time required to find a suitable match has led to the use of cord blood and haploidentical related donors as stem cell sources. For children who relapse, SCT is likely to remain the principal option to promote survival. Efforts to reduce both the risk of relapse and the transplant regimen toxicity, both immediate and delayed, must continue.

References

Nov 26, 1998·The New England Journal of Medicine·P RubinsteinC E Stevens
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F BouladR J O'Reilly
Apr 6, 2000·The New England Journal of Medicine·M AricòG Masera
Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·U M Saarinen-PihkalaUNKNOWN Nordic Society of Pediatric Hematology and Oncology
Mar 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Franco AversaMassimo F Martelli
Nov 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hagen Graf EinsiedelGünter Henze
Dec 13, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·David A JacobsohnMorris Kletzel
Jan 13, 2006·The New England Journal of Medicine·Ching-Hon Pui, William E Evans
Dec 21, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·André SchrauderMartin Schrappe
Dec 30, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jose-Maria RiberaGuillermo Deben
Jan 24, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Prakash SatwaniMitchell S Cairo
Jun 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Adriana BalduzziMaria Grazia Valsecchi

❮ Previous
Next ❯

Citations

Jul 19, 2013·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Byung Woog KangSang Kyun Sohn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.